HBIO Harvard Bioscience Inc.

Harvard Bioscience Schedules First Quarter 2020 Earnings Conference Call for May 5, 2020 at 8:00 AM ET

Harvard Bioscience Schedules First Quarter 2020 Earnings Conference Call for May 5, 2020 at 8:00 AM ET

HOLLISTON, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2020 before the market opens on May 5, 2020, and will hold a conference call to discuss the results on May 5, 2020 at 8:00 a.m. Eastern Time.

You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 3848975.

The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to  and click on the Earnings Call icon. The webcast will be available on the website through May 12, 2020.

Financial information presented on the call, including the earnings release, will be available on the investor relations section of Harvard Bioscience’s website.

About Harvard Bioscience

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and clinical research organizations. With operations in North America and Europe, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at .

Investor Contact

Michael Rossi

Chief Financial Officer

(508) 893-8999

EN
23/04/2020

Underlying

HBIOHarvard Bioscience Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Second Quarter 2025 Financial Results

Harvard Bioscience Announces Second Quarter 2025 Financial Results Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025. “We made solid progress in the second quarter exceeding our rev...

August 11, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference C...

Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join...

August 4, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two ...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO followi...

July 17, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Appoints John Duke to Board of Directors

Harvard Bioscience Appoints John Duke to Board of Directors HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company’s board of directors. “We are pleased to welcome John to Harvard Bioscience’s board,” said Katherine Eade, Lead Independent Director. “John brings ...

June 2, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces First Quarter 2025 Financial Results

Harvard Bioscience Announces First Quarter 2025 Financial Results HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China.” We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid syst...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch